Celldex Therapeutics
CLDX· Manufacturing· Fiscal year ends in December· Structured data only: no proxy read yet
No proxy on file names the CEO of Celldex Therapeutics.
Executives5
See all- 1Anthony S. MarucciNot disclosed
- 2Elizabeth CrowleyNot disclosed
- 3Margo Heath-ChiozziNot disclosed
- 4Sam MartinNot disclosed
- 5Tibor Keler.Not disclosed
Named executives and their total pay, from the Summary Compensation Table of the latest proxy.
Peers24
See allThe FY2025 (Dec) proxy of Celldex Therapeutics names 24 peer companies for pay. Among Celldex Therapeutics and these peers, CEO pay was 9th highest of 10 and total shareholder return was 4th highest of 10.
9th highest of 10in Celldex Therapeutics and its pay peers, FY2025 (Dec) by CEO pay:
4th highest of 10in Celldex Therapeutics and its pay peers, FY2025 (Dec) by total shareholder return:
%20scale(0.100000,-0.100000)'%20fill='%23000000'%20stroke='none'%3e%3cpath%20d='M3195%205489%20c-380%20-49%20-706%20-317%20-831%20-682%20-56%20-163%20-54%20-112%20-54%20-1773%20l0%20-1534%20590%200%20590%200%200%201465%200%201465%20600%200%20600%200%200%20535%200%20535%20-712%20-1%20c-392%20-1%20-744%20-6%20-783%20-10z'/%3e%3c/g%3e%3c/svg%3e)
The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year.
Board1
See all- Herbert J. ConradDirector · 19 yr on the boardIndependentNominating and Corporate Governance (Chair)—Paid as an executive
The board of the latest proxy (FY2023).
Activity
No new filings about this company in the feed.
Filings6
See all| Proxy statement | DEF 14A | Apr 29, 2026 | FY2025 |
| Annual report | 10-K | Feb 25, 2026 | FY2025 |
| Proxy statement | DEF 14A | Apr 21, 2025 | FY2024 |
| Annual report | 10-K | Feb 27, 2025 | FY2024 |
| Proxy statement | DEF 14A | Apr 25, 2024 | FY2023 |
| Annual report | 10-K | Feb 26, 2024 | FY2023 |
